Key highlights
- Optiscan Imaging fell 10.71% to $0.125, Cettire fell 10.91% to $0.245 and Innovaero fell 10.00% to $0.225 at 11:04 AM AEDT on 19 November 2026.
- Optiscan lodged two US FDA 510(k) submissions for its InForm and InVue devices after quarter end.
- Cettire reported gross Revenue of $331.0 million for the four months to 31 October 2026, up 18%.
Three small-cap ASX companies fell in mid-morning trade on 19 November 2026, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. Optiscan Imaging Ltd (ASX:OIL) traded at $0.125, down 10.71%. Cettire Limited (ASX:CTT) traded at $0.245, down 10.91%, and Innovaero Technologies Limited (ASX:INN) traded at $0.225, down 10.00%. The companies cover medical imaging, online luxury retail and aerospace and defence systems. The figures quoted are intraday prices at 11:04 AM AEDT on 19 November 2026, reflecting trade in progress at that time rather than closing prices. Each share price is shown as traded during the session, so later moves may differ from the figures quoted here. The S&P/ASX 200 figures are the level and percentage change quoted at midday on the same day. The companies named in this article are each covered in their own section below, with the release date for the update shown where it applies. Investors reading these figures should note that the prices are from the Trading session and do not represent a closing price for the day. The percentage changes are those shown for each company in the price table used for this article. Each company section sets out the most recent update that the company has released, with the date of that update stated in the text.
Optiscan Imaging (ASX:OIL): FDA Submissions
Optiscan Imaging reported in its quarterly activities report dated 30 October 2026 that it lodged two US FDA 510(k) submissions for its InForm digital pathology device and its InVue precision surgery device shortly after the quarter ended 30 September 2026. The company signed two research agreements with the Mayo Clinic and launched its InSpecta product in the US veterinary market. It invested $1.957 million in Research and Development during the quarter.
The InVue device is designed for precision surgery, while InForm is a digital pathology device. Chief executive Dr Camile Farah said the submissions move the company’s lead human-use platforms into formal FDA review and bring it closer to potential entry into US digital pathology and precision surgery markets.
Cettire (ASX:CTT): Four-Month Trading Update
Cettire released a trading update on 18 November 2026 for the four months to 31 October 2026. Gross revenue was $331.0 million, up 18%, and sales revenue was $246.2 million, up 15%. Delivered Margin rose to $42.2 million, and adjusted EBITDA was $6.9 million, up from $4.6 million. Cash was $27 million with no financial debt, and active customers reached about 650,000. Revenue outside the United States grew 36%, while US gross revenue fell 3%.
Founder and chief executive Dean Mintz said the company is achieving continued Market Share gains and improving profitability. Average order value fell 3% to A$914, and gross revenue from repeat customers was 65%, compared with 68% a year earlier. Adjusted EBITDA excludes share-based payments and foreign exchange items.
Innovaero (ASX:INN): First Quarterly Report After Listing
Innovaero listed on the ASX on 22 September 2026 and released its first quarterly activities report on 23 October 2026. The company reported cash of A$42.9 million after a A$40 million initial public offering at A$0.50 per share. Its Misson Talon Strike program delivered A$3 million of revenue, with a further A$13 million due by 31 March 2027, subject to certification. Its Eagleview contract deliveries remain on target, with A$2.1 million due in the second quarter of FY27.
Innovaero said the Misson Talon Strike program is subject to successful certification with the Australian Defence Force, and that the next order is expected shortly after certification. The company is scaling production capability, and its maintenance, repair and overhaul division added two customers, including Pilatus.






Please wait processing your request...